RAPT Therapeutics (RAPT) Cash from Operations (2020 - 2024)
Historic Cash from Operations for Therapeutics (RAPT) over the last 5 years, with Q4 2024 value amounting to -$10.4 million.
- Therapeutics' Cash from Operations rose 6238.38% to -$10.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$83.3 million, marking a year-over-year increase of 1416.62%. This contributed to the annual value of -$83.3 million for FY2024, which is 1416.62% up from last year.
- Per Therapeutics' latest filing, its Cash from Operations stood at -$10.4 million for Q4 2024, which was up 6238.38% from -$17.6 million recorded in Q3 2024.
- In the past 5 years, Therapeutics' Cash from Operations ranged from a high of -$6.4 million in Q2 2020 and a low of -$28.8 million during Q2 2023
- For the 5-year period, Therapeutics' Cash from Operations averaged around -$17.6 million, with its median value being -$16.4 million (2022).
- Its Cash from Operations has fluctuated over the past 5 years, first crashed by 11652.4% in 2021, then skyrocketed by 6238.38% in 2024.
- Quarter analysis of 5 years shows Therapeutics' Cash from Operations stood at -$15.4 million in 2020, then plummeted by 34.59% to -$20.7 million in 2021, then fell by 10.48% to -$22.8 million in 2022, then dropped by 21.47% to -$27.8 million in 2023, then skyrocketed by 62.38% to -$10.4 million in 2024.
- Its Cash from Operations stands at -$10.4 million for Q4 2024, versus -$17.6 million for Q3 2024 and -$28.2 million for Q2 2024.